Appili Therapeutics Inc Class A

As of June 30, 2026, Appili Therapeutics Inc Class A carries a market capitalization of 1.99M, placing it among publicly traded companies globally. Its enterprise value stands at 15.17M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Appili Therapeutics Inc Class A's next confirmed earnings release is scheduled for November 12, 2026.

As of June 30, 2026, Appili Therapeutics Inc Class A has 132.37M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 5.33, and the price-to-book ratio stands at -0.10.

These figures are as of June 30, 2026. The EV/Sales ratio of 41.91 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 15.17M versus a market cap of 1.99M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Appili Therapeutics Inc Class A maintains a current ratio of 0.07, meaning it holds 0.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -70.05, indicating conservative leverage, while an interest coverage ratio of -2.35 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -293.37, reflecting losses generated across the asset base. The company generates approximately 51,724.71 in revenue per employee across its workforce of 7.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Appili Therapeutics Inc Class A recorded 92,925.00 in income tax expense. The company reported a pretax loss of -4.59M and -4.69M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 2, 2026, Appili Therapeutics Inc Class A's stock has declined approximately 85.71% over the past 52 weeks. The 50-day moving average sits at 0.01, while the 200-day moving average is 0.02.

Over the twelve months ended June 30, 2026, Appili Therapeutics Inc Class A generated 362,073.00 in revenue and converted that into -4.69M in net income, yielding earnings per share of -0.04. EBITDA reached -4.00M, while operating income came in at -4.00M.

As of June 30, 2026, Appili Therapeutics Inc Class A holds 138,680.00 in cash and equivalents against 13.33M in total debt, resulting in a net debt position of 13.19M. Total book value stands at -19.02M, with working capital of -18.39M providing operational flexibility.

Appili Therapeutics Inc Class A produced -1.37M in operating cash flow over the twelve months ended June 30, 2026. After subtracting - - in capital expenditures, free cash flow totaled -1.37M - equivalent to -0.01 per share.

These figures cover the twelve months ended June 30, 2026. The operating margin of -1,105.03 and net profit margin of -1,294.52 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Appili Therapeutics Inc Class A paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -70.92: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -18.33, meaning Appili Therapeutics Inc Class A raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Appili Therapeutics Inc Class A has an Altman Z-Score of -110.84, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.